3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
1 Top AI Stock For Next Bull Market
Investment Alert: Buy C3.AI Under $17
Disclaimer: Ivy Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
The global artificial intelligence research market is estimated to be $119 billion in 2022 according to Precedence Research.
» Read more about: 1 Top AI Stock For Next Bull Market »
Read More
52.7% Upside In Top Growth Stock
Investment Alert: Buy ZM Under $71/share; Sell $105
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
When lockdowns swept the world,
» Read more about: 52.7% Upside In Top Growth Stock »
Read More
Will Shiba Inu Hit $1?
It’s no mean feat for a token to rise to public notoriety given that tens of thousands of them currently exist. But Shiba Inu is that rare token that captured the public’s attention, at least for a while. Trading now at $0.00001097, the question looms: Will Shiba Inu hit $1?
Meme Token Bubble
At its peak in October 2021,
» Read more about: Will Shiba Inu Hit $1? »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Pepsi’s Dividend Near All-time Highs
PepsiCo just kicked off 2025 on the wrong foot, posting disappointing first-quarter results and slashing its full-year guidance. The market didn’t take it lightly. Shares tumbled to a fresh 52-week low, and are now down over 19.8% over the 6 months, approaching levels not seen in nearly five years.
But here’s the twist,
» Read more about: Pepsi’s Dividend Near All-time Highs »
Read MoreThe Spotlight
Spotlight: Turn $15k Into $1,000 Every Year
When we first spotlighted Verizon, it had a yield that approached 8% but after its recent move higher, it still offers a handsome yield of over 6.4%.
That’s more than enough to turn a $15,000 investment into an annual payout of $1,000+, assuming the dividend stays in place, but will it?
Here’s what you need to know about Verizon and its potential to pay a steady income stream for the foreseeable future.
» Read more about: Spotlight: Turn $15k Into $1,000 Every Year »
Read MoreThe Daily
What the Options Market Tells Us About ON Semiconductor
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $75.0 for ON Semiconductor over the last 3 months.
» Read more about: What the Options Market Tells Us About ON Semiconductor »